

Miyagawa CPA Office

No.32 Arai Building 6F,3-9-14, Kudanminami, Chiyoda-ku, Tokyo, Japan

Independent auditor's report

To the members of Neuland Laboratories K.K.

Report on the accounts for the year ended on March 31,2026 in compliance with Japanese Company law.

We have audited the attached balance sheet of Neuland Laboratories K.K., as of March 31,2026 and 2025, and also the profit and loss account for the years ended on those dates. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.


We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

We report that:

- a. We have obtained all the information and explanations, which to the best of our knowledge and belief, were necessary for the purposes of our audit.
- b. In our opinion, proper books of account as required by law have been kept by the company so far as appears from our examination of those books.
- c. The balance sheet and profit and loss account dealt with by this report are in agreement with the books of account.

- d. In our opinion, the balance sheet and profit and loss account dealt with by this report comply with the generally accepted accounting standards.
- e. In our opinion and to the best of our information and according to the explanations given to us, the said accounts give the information required by the Company law in manner so required and give a true and fair view in conformity with the accounting principles generally accepted in Japan.
 - i . in the case of the balance sheet, of the state of affairs of the company as of March 31,2026.
 - ii . in the case of the profit and loss account, of the income for the year ended on that date.

for Miyagawa CPA Office



Jitsuo Miyagawa
(Japanese Certified Public Accountant)
April 20,2026

Neuland Laboratories K.K.

BALANCE SHEET AS OF MARCH 31, 2026 and MARCH 31,2025

Unit:JPY

	Note to account	Year ended 31 March 2026	Year ended 31 March 2025
Assets			
Current assets			
Cash&deposit		20,532,044	16,740,413
Accounts receivables- Affiliates	1	11,802,954	13,265,349
Accounts receivables- Service fee			
Prepaid expenses-Rent		388,311	388,311
Prepaid expenses-Others		246,900	569,000
Advance payment		28,220	20,646
Consumption taxes(VAT)		1,268,472	1,282,465
Current assets total		34,266,901	32,266,184
Fixed assets			
Tangible assets		366,665	521,609
Intangible assets			
Investment & other assets			
Deposit for rent		2,841,300	2,841,300
Long -term prepaid expenses		165,740	23,672
Fixed assets total		3,373,705	3,386,581
Assets total		37,640,606	35,652,765
Liabilities			
Current liabilities			
Accounts payable /Accrued expenses		489,165	654,875
Withholding social insurance		383,649	391,743
Withholding income & local taxes		1,077,490	1,165,445
Advance received			
Provision for corporate income taxes		236,800	1,152,100
Current liabilities total		2,187,104	3,364,163
Fixed liabilities			
Provision for retirement allowances		12,009,382	10,314,246
Fixed liabilities total		12,009,382	10,314,246
Liabilities total		14,196,486	13,678,409
Net assets			
Shareholder's equity			
Paid in capital		3,000,000	3,000,000
Capital surplus			
Earned surplus			
Other earned surplus			
Earned surplus carried forward		18,974,356	18,086,584
(Net profit for the year)		(1,469,764)	(887,772)
Earned surplus total		20,444,120	18,974,356
Net assets total		23,444,120	21,974,356
Net assets/Liabilities total		37,640,606	35,652,765

Neuland Laboratories K.K.

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED MARCH 31, 2026 and MARCH 31,2025

Unit:JPY

	Note to account	Year ended 31 March 2026	Year ended 31 March 2025
Income			
Seervice fee income	1	52,302,954	52,965,349
Gross income		52,302,954	52,965,349
General and administration expenses	2	49,512,338	50,443,190
Operating profit		2,790,616	2,522,159
Other operating income		38,748	11,713
Interest income		37,648	10,609
Others		1,100	1,104
Other operating expenses		300,000	
Interest expenses			
Others		300,000	
Ordinary profit		2,529,364	2,533,872
Extraordinary item			
Others			
Profit before taxes		2,529,364	2,533,872
Corporate tax,resident tax & business tax		1,059,600	1,646,100
Deferred taxes			
Net income for the year		1,469,764	887,772

Neuland Laboratories K.K.

SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING AND USE OF ESTIMATES

- i . Financial statements are prepared under the historical cost convention, on accrual basis of accounting in accordance with the accounting principles generally accepted in Japan and in compliance with the provisions of Company's law.
- ii . The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities if any at that date of the financial statements and the results of operations during the reporting period end.

B. REVENUE RECOGNITION

The company is engaged primarily in the support of active pharmaceutical ingredient, marketing and business support services on behalf of the parent company. The service fee for the support is calculated as 105% of the incurred expenses related to the support. The treatment is recognized by the Japanese tax authority.

C. TAXATION

Tax expenses comprises of current taxes. Current income tax is measured at the amount to be paid to the tax authorities in Japan.

NOTES TO ACCOUNT

1. Intercompany Account

Intercompany Accounts	Year ended 31 March 2026	Year ended 31 March 2025
Accounts receivable	11,802,954	13,265,349
Suspense received		
Service fee	52,302,954	52,965,349

2.Details of General and administration expenses

Accounts	Year ended 31 March 2026	Year ended 31 March 2025
Advertising & Promotion	4,015,040	4,083,798
Delivery expenses	100,549	42,008
Salaries	25,658,088	26,605,640
Commutation fee	576,494	669,276
Social insurance	2,633,028	2,916,741
Recruiting fee		
Retirement allowance	1,695,136	1,559,376
Depreciation expense	154,944	85,072
Office supplies	90,480	120,271
Water,lighting fee	66,995	60,343
Traveling expenses	8,369,542	8,616,724
Commision paid(bank charge)	53,720	46,988
Taxes(Inc.Revenue stamp)	6,215	12,223
Entertainment expenses	223,624	431,198
Communication fee	554,981	406,535
PC maintenance	14,500	14,500
Book & subscription fee	31,327	5,000
Meeting expenses	339,493	210,000
Rent of office	4,236,120	4,236,120
Deferred renewal fee	142,062	142,068
Professional service fee	550,000	179,309
Total General and administration expenses	49,512,338	50,443,190
Others		
TOTAL	49,512,338	50,443,190

Neuland Laboratories K.K.

PROFIT AND LOSS ACCOUNT

Description	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Sales		
Services Fee income	52,302,954	52,965,349
Gross Sales	52,302,954	52,965,349
Administration, selling expenses	49,512,338	50,443,190
Operating Profit	2,790,616	2,522,159
Other operating income	38,748	11,713
Interest Income	37,648	10,609
Others	1,100	1,104
Other operating expenses	300,000	-
Interest Expenses	-	-
Others	300,000	-
Ordinary Profit	2,529,364	2,533,872
Extraordinary Item	-	-
Others	-	-
Profit before taxes	2,529,364	2,533,872
Corporate, Residential & Business Taxes	1,059,600	1,646,100
Deferred Taxes	-	-
Net Income for the Year	1,469,764	887,772

Company :
Neuland Laboratories K.K.

Auditor :
Miyagawa CPA Office

(Signature) 
Name : Yasukazu Ogino

(Signature) 
Name : Hisuo Miyagawa

(Signature) 
Name : Mamoru Shizuishi

Neuland Laboratories K.K.

NOTES TO ACCOUNT

Intercompany Account

	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Intercompany Accounts		
Account Receivable	11,802,954	13,265,349
Suspense Received	-	-
Service Fee	52,302,954	52,965,349

Details of Administration, selling expenses

Accounts	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Advertising & Promotion	4,015,040	4,083,798
Delivery expenses	100,549	42,008
Salaries	25,658,088	26,605,640
Commutation fee	576,494	669,276
Social Insurance	2,633,028	2,916,741
Recruiting Fees		
Retirement expenses	1,695,136	1,559,376
Depreciation Expenses	154,944	85,072
Office Supplies	90,480	120,271
Water, lighting fee	66,995	60,343
Travelling expenses	8,369,542	8,616,724
Commission Paid (Bank Charge)	53,720	46,988
Taxes (Inc. Revenue stamp)	6,215	12,223
Entertainment expenses	223,624	431,198
Communication Fee	554,981	406,535
Pc Maintenance	14,500	14,500
Book & Subscription and Membership fee	31,327	5,000
Meeting expenses	339,493	210,000
Rent of office	4,236,120	4,236,120
Deferred renewal fee	142,062	142,068
Professional Service Fee	550,000	179,309
Total Administration & selling expenses	49,512,338	50,443,190
Others	-	-
TOTAL	49,512,338	50,443,190

Neuland Laboratories K.K.
BALANCE SHEET

unit : Yen


Description	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Assets		
Current assets		
Cash & Deposit	20,532,044	16,740,413
Accounts receivable - Affiliates	11,802,954	13,265,349
Accounts receivable - Services fee	-	-
Prepaid expenses - Rent	388,311	388,311
Prepaid expenses - Others	246,900	569,000
Advance payment	28,220	20,646
Consumption taxes (VAT)	1,268,472	1,282,465
Current Assets Total	34,266,901	32,266,184
Fixed Assets		
Tangible Assets	366,665	521,609
Intangible Assets	-	-
Investments & other Assets		
Deposit for rent	2,841,300	2,841,300
Long - term Prepaid expenses	165,740	23,672
Investments & other Assets total	3,007,040	2,864,972
Fixed Assets total	3,373,705	3,386,581
Assets total	37,640,606	35,652,765
Liabilities		
Current liabilities		
Accounts payable / Accrued expenses	489,165	654,875
Withholding Social Insurance	383,649	391,743
Withholding Income & Local Taxes	1,077,490	1,165,445
Advance Received	-	-
Provision for Corporate Income Taxes	236,800	1,152,100
Current Liabilities total	2,187,104	3,364,163
Fixed Liabilities		
Provision for retirement allowances	12,009,382	10,314,246
Fixed Liabilities total	12,009,382	10,314,246
Liabilities total	14,196,486	13,678,409
Net Assets		
Shareholder's equity		
Paid in Capital	3,000,000	3,000,000
Capital Surplus	-	-
Earned Surplus		
Other Earned Surplus	-	-
Earned Surplus carried forward	18,974,356	18,086,584
Net Profit for the Year	1,469,764	887,772
Earned Surplus total	20,444,120	18,974,356
Net Assets Total	23,444,120	21,974,356
Net Assets /Liabilities Total	37,640,606	35,652,765

Company :
Neuland Laboratories K.K.

Auditor :
Miyagawa CPA Office

(Signature) 
Name : Yasukazu Ogino

(Signature) 
Name : Jitsuo Miyagawa

(Signature) 
Name : Mamoru Shizuishi